Head & Neck Trials
A list of our early phase head and neck trials which are open to recruitment at University College London Hospitals.
Additional early phase clinical trials recruiting Head & Neck cohorts may be found in the Advanced Solid Tumour Trials Portfolio page.
OrigAMI-4A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | |
|---|---|
| IRAS Number: | 1009340 |
| Principal Investigator: | Prof Martin Forster |
| Drug Class/ Treatment: | Amivantamab (EGF Receptor and MET Receptor-directed antibody) Monotherapy and combination with SOC |
| Patient Population: | Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) |
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
Principal Investigator(s)
Professor Martin Forster
Associate Professor / Consultant Medical Oncologist / UCL ECMC Clinical Lead
